Best Omega-3 Supplements for Heart Health in 2026

EPA reduces cardiovascular risk through several overlapping mechanisms, and the science here is more detailed than 'fish oil is good for your heart.' First, triglyceride reduction. EPA inhibits the hepatic enzyme diacylglycerol acyltransferase, reducing the liver's production of VLDL particles (the precursors to triglycerides in your blood). At doses of 2-4g daily, this can lower triglycerides by 20-45%. That's a meaningful shift for people with levels above 150 mg/dL. Second, plaque stabilization. Arterial plaques don't cause heart attacks by slowly clogging arteries — they cause heart attacks by rupturing. EPA incorporates into the phospholipid membranes of cells within arterial plaque, and research suggests this makes plaques more stable and less prone to rupture. The EVAPORATE trial found that EPA reduced plaque volume over 18 months. Third, anti-inflammatory pathways. EPA is converted into resolvins (specifically resolvin E1 and E2), which actively resolve inflammation rather than merely suppressing it. Chronic vascular inflammation is a recognized driver of atherosclerosis, and EPA's anti-inflammatory action is distinct from that of NSAIDs or statins. An important nuance: DHA, while beneficial in other contexts, may slightly raise LDL cholesterol in some individuals. This is one reason EPA-dominant (or pure EPA) formulations show stronger cardiovascular outcomes in trials. ### What REDUCE-IT actually showed (and didn't show) The **REDUCE-IT trial** (NEJM 2019) is the most-cited randomized evidence for cardiovascular benefit from a long-chain omega-3 product. Important context for interpreting it on this page: - The active intervention was **icosapent ethyl** (brand name Vascepa), a prescription pharmaceutical-grade product containing only purified EPA at 4 grams daily. **It is not the same as over-the-counter fish oil**, which contains a mixture of EPA, DHA, and other fatty acids in lower concentrations. - The trial enrolled 8,179 patients who were already on statin therapy, with elevated triglycerides (≥150 mg/dL) and high cardiovascular risk. Generalizing to people without these risk factors, who are not on statins, or who are taking standard fish oil rather than prescription EPA, is not directly supported by the trial. - The trial used a mineral oil placebo. Some analyses have raised concerns that the placebo arm showed adverse changes in inflammatory and oxidative biomarkers, which would partially inflate the apparent benefit of icosapent ethyl. The trial's investigators have argued that even if mineral oil had pro-inflammatory effects, they would not be sufficient to explain the magnitude of clinical benefit observed. Two larger trials of standard omega-3 supplementation produced different results: - **STRENGTH** (JAMA 2020) tested a different prescription omega-3 (omega-3 carboxylic acids, 4g daily) in 13,078 patients with high CV risk and elevated triglycerides. The trial was stopped for futility — there was no cardiovascular benefit vs corn oil placebo. - **VITAL** (NEJM 2018) tested 1g daily of standard EPA + DHA fish oil in 25,871 generally healthy older adults. There was no significant reduction in major cardiovascular events versus placebo. The honest summary: prescription EPA-only icosapent ethyl reduced CV events in a high-risk, statin-treated, hypertriglyceridemic population, but standard OTC fish oil at typical doses has not been shown to reduce cardiovascular events in broader populations.

For cardiovascular health, EPA content per serving is the single most important number on the label. The trials that moved the needle — REDUCE-IT and JELIS — used EPA-dominant or pure-EPA protocols. DHA is fine to include (and all fish oil naturally contains some), but don't optimize for it when your goal is heart health. Here's a practical reality check: the REDUCE-IT trial used 4g/day of purified EPA. That's a prescription-grade dose (Vascepa/icosapent ethyl) that's difficult to replicate with over-the-counter fish oil. At 800mg EPA per serving, you'd need 5 servings of Carlson's product daily to match REDUCE-IT doses. That's impractical and expensive. For most people, 1-2g EPA daily from a quality supplement is a reasonable over-the-counter strategy — it won't replicate REDUCE-IT exactly, but it's far better than nothing. IFOS certification matters especially for fish oil you're taking long-term. Rancid (oxidized) fish oil may actually increase inflammation rather than reduce it. IFOS tests oxidation levels alongside heavy metals and potency. Three of our four picks carry this certification. One thing to watch: some omega-3 products marketed for heart health bundle in CoQ10, garlic extract, or red yeast rice. These additions are generally underdosed compared to standalone supplements. You're better off buying a quality fish oil and adding targeted supplements separately if needed.